TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1911008
Drug: Intermittent i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent i.m. injection of ketorolac 10 mg administered 4-hourly
Study: 7139397
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of succinylcholine (self-taming)
Study: 7139397
Drug: d-tubocurarine 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-tubocurarine 0.04 mg/kg
Study: 20616673
Drug: 17beta‐E2 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐E2 (1 mg/d for 1 mo, then 2 mg/d for 2 mo)
Study: 16140224
Drug: cetirizine 10mg
Normalized name: CETIRIZINE 10MG/ML INJ
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cetirizine 10mg daily
Study: 6143538
Drug: Betaxolol 5
Normalized name: betaxolol 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 5 mg
Study: 2573178
Drug: Betaxolol 10
Normalized name: betaxolol 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 10 mg
Study: 6761136
Drug: Betaxolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 40 mg
Study: 20845391
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of melatonin every night for 14 days or until discharge
Study: 19438696
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine
Study: 19438696
Drug: Infra-low-dose dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infra-low-dose dipyridamole
Study: 9919901
Drug: FUT-175 (40-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUT-175 (40-160 mg/day) administered during the initial 4 days following surgery
Study: 1976298
Drug: Oral astemizole
Normalized name: Astemizole
DrugBank: Astemizole (DB00637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral astemizole for 8 weeks
Study: 31758576
Drug: PF-06480605 1
Normalized name: PF-05180999
DrugBank: PF-05180999 (DB14885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06480605 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, or 800 mg IV (SAD)
Study: 31758576
Drug: PF-06480605 3
Normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06480605 3 × 500 mg IV, or 3 × 30 mg, 3 × 100 mg, or 3 × 300 mg SC every 2 weeks for three doses (MAD)
Study: 31156217
Drug: Ampasse (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampasse (5, 10, or 25 mg intravenously once a day for 15 days)
Study: 28076709
Drug: 177Lu-Dotatate (7.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-Dotatate (7.4 GBq every 8 weeks, plus best supportive care including octreotide LAR 30 mg IM)
Study: 28076709
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR (60 mg IM every 4 weeks)
Study: 19135496
Drug: SC599 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC599 vaccine 10^5 CFU
Study: 19135496
Drug: SC599 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC599 vaccine 10^7 CFU
Study: 19135496
Drug: SC599 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC599 vaccine
Study: 17920547
Drug: Antigen-specific therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antigen-specific therapy targeting myelin proteins
Study: 15239532
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily chest physiotherapy
Study: 12575568
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese and Western medicine (TCM-WM) for over 10 months
Study: 12575568
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory and analgesic agents
Study: 12575568
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese and Western medicine (TCM-WM)
Study: 9591935
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice with 10 mg felodipine ER
Study: 9591935
Drug: Control (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (water with 10 mg felodipine ER)
Study: 2533057
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg celiprolol daily
Study: 2533057
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg celiprolol daily
Study: 29137506
Drug: Labeled Cash
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labeled Cash Transfer with Commitment (L-CCT)
Study: 23265698
Drug: Peanut doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut doses through the Week 44 OFCs
Study: 16478899
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d of rimonabant
Study: 15246619
Drug: RIX4414 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 vaccine (two doses at 2 and 4 months of age)
Study: 15246619
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two doses at 2 and 4 months of age)
Study: 9088653
Drug: Flunisolide nasal
Normalized name: flunisolide nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide nasal spray 50 micrograms twice/daily (Group 1)
Study: 9088653
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) 10.4 mg three times/day (Group 2)
Study: 30541745
Drug: Standard combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combination of daunorubicin and cytarabine ('7+3')
Study: 20604812
Drug: Mandibular implant-retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mandibular implant-retained overdentures (MIRO) with maxillary dentures (MCD) using two implant-ball attachments (BC)
Study: 20604812
Drug: Mandibular implant-retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mandibular implant-retained overdentures (MIRO) with maxillary dentures (MCD) using four implants-bar attachments (BRC)
Study: 20604812
Drug: Mandibular implant-retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mandibular implant-retained overdentures (MIRO) with maxillary fixed partial dentures (MFPD) using two implant-ball attachments (BF)
Study: 10091344
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin (0.5%)
Study: 6822143
Drug: Clonidine 0.1
Normalized name: clonidine 0.17 MG
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 0.1 mg twice daily
Study: 6822143
Drug: Clonidine 0.2
Normalized name: CLONIDINE 0.2MG/24HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.2 mg twice daily (for those not achieving blood pressure goals)
Study: 6822143
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg twice daily (for those not achieving blood pressure goals)
Study: 29141373
Drug: 0.08% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08% ropivacaine and 15 μg/ml hydromorphone (H1 group)
Study: 29141373
Drug: 0.10% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10% ropivacaine and 15 μg/ml hydromorphone (H2 group)
Study: 29141373
Drug: 0.12% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% ropivacaine and 15 μg/ml hydromorphone (H3 group)
Study: 29141373
Drug: 0.12% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% ropivacaine plus 20 μg/ml hydromorphone (first 50 women)
Study: 7493146
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (5 ml)
Study: 29032494
Drug: Exenatide +
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide + insulin
Study: 8408474
Drug: Insulin only
Normalized name: Isophane insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin only
Study: 27498355
Drug: BiP 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiP 5 mg
Study: 27498355
Drug: BiP 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiP 15 mg
Study: 27498355
Drug: BiP 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiP 1 mg
Study: 27498355
Drug: BiP (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiP (5 mg and 15 mg)
Study: 16621911
Drug: Ghrelin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin infusion (5.0 pmol/kg.min) during hyperinsulinemic euglycemic clamp
Study: 16621911
Drug: Ghrelin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin infusion (5.0 pmol/kg.min)
Study: 10798540
Drug: LH-RH agonist
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-RH agonist monotherapy (leuprorelin acetate depot, 3.75 mg monthly)
Study: 10798540
Drug: LH-RH agonist
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-RH agonist in combination with chlormadinone acetate (100 mg/day)
Study: 1558340
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus ranitidine
Study: 3894147
Drug: Gemeprost (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemeprost (1 mg vaginal pessary)
Study: 29743076
Drug: Daily Mile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Mile intervention
Study: 27238921
Drug: POD treatment
Normalized name: Senna pod
Approvals — FDA: no, EMA: no, PMDA: no
Description: POD treatment (scaling, root planing, and subantimicrobial dose doxycycline)
Study: 27238921
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to doxycycline therapy
Study: 19783106
Drug: Naltrexone and
Normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone and psychosocial treatment for alcohol dependence
Study: 19783106
Drug: Naltrexone and
Normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone and psychosocial treatment for comorbid alcohol and cocaine dependence
Study: 16267634
Drug: Quetiapine (589.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (589.7 mg/day)
Study: 16267634
Drug: Risperidone (4.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4.9 mg/day)
Study: 12164745
Drug: UV‐B phototherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV‐B phototherapy (3-times weekly narrowband TL‐01 UV‐B regimen)
Study: 12164745
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients awaiting UV‐B therapy)
Study: 7772441
Drug: lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 60 mg
Study: 2193199
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (1 unit.kg bw‐1.hr‐1)
Study: 148436
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide gels
Study: 11015150
Drug: Gradual initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Gradual initiation of TMP/SMX suspension
Study: 11015150
Drug: Routine initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Routine initiation of double-strength (DS; 160 mg/800 mg) tablets
Study: 1619985
Drug: E +
Normalized name: Perle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: E + C (ephedrine 20 mg/caffeine 200 mg)
Study: 26771947
Drug: Clinical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical management combined with pharmacotherapy (CM+MED)
Study: 16207425
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with recombinant tissue‐type plasminogen activator (rtPA) intravenously
Study: 16207425
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy with low molecular weight heparin
Study: 11910672
Drug: 40‐mg isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40‐mg isoflavone supplement (one tablet per day)
Study: 2039897
Drug: Bladder retraining
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder retraining and terodiline 25 mg daily
Study: 30040762
Drug: Bimanual training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimanual training with error augmentation
Study: 30040762
Drug: Bimanual training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimanual training without error augmentation
Study: 19846114
Drug: Guided resistance
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided resistance training twice weekly for 4 months (team GCK)
Study: 15928801
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (one tab/week)
Study: 10599727
Drug: GH dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH dosage group A, 4 IU/m2 day (approximately 0.045 mg/kg x day)
Study: 10599727
Drug: GH dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH dosage group B, first year 4 IU/m2 x day, thereafter 6 IU/m2 x day (approximately 0.0675 mg/kg/day)
Study: 10599727
Drug: GH dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH dosage group C, first year 4 IU/m2 x day, second year 6 IU/m2 x day, thereafter 8 IU/m2 x day (approximately 0.090 mg/kg x day)
Study: 10599727
Drug: GH dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH dosage group A
Study: 10599727
Drug: GH dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH dosage group B
Study: 10599727
Drug: GH dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH dosage group C
Study: 7774515
Drug: Ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5 or 5 mg/day
Study: 7774515
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 or 10 mg/day
Study: 7774515
Drug: Ramipril with
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril with diuretics (hydrochlorothiazide or piretanide)
Study: 27224980
Drug: TAU (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU (Treatment as usual)
Study: 26058405
Drug: Cold-gel packing
Normalized name: menthol Topical Gel [Cold Spot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-gel packing
Study: 22882759
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of natural progesterone
Study: 22882759
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of natural progesterone
Study: 19803419
Drug: BNP/NT-proBNP-guided therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP/NT-proBNP-guided therapy
Study: 17557771
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate (SFC) 50 microg salmeterol and 500 microg fluticasone propionate twice daily for 3 months
Study: 17557771
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 500 microg twice daily for 3 months
Study: 9651466
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg twice daily), clarithromycin (250 mg twice daily), and tinidazole or metronidazole (500 mg twice daily) for 1 week
Study: 9651466
Drug: Standard metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard metronidazole and bismuth combination therapies
Study: 7986443
Drug: Subgingival irrigation
Normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival irrigation with amine fluoride-stannous fluoride gel
Study: 2637081
Drug: Dissolved cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dissolved cisplatin (30 mg/24 hours)
Study: 2637081
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment with dissolved cisplatin (50 mg/die)
Study: 25919966
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for both aspirin and celecoxib)
Study: 21306414
Drug: Linagliptin 100
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin 100 mg
Study: 19673817
Drug: Receptive music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receptive music therapy programs
Study: 16495394
Drug: Denosumab (6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (6, 14, or 30 mg every three months or 14, 60, 100, or 210 mg every six months)
Study: 15525311
Drug: Topical bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bupivacaine (0.25%)
Study: 9629990
Drug: Cordaflex 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cordaflex 20 mg retard filmtablet after fasting
Study: 9629990
Drug: Cordaflex 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cordaflex 20 mg retard filmtablet after food ingestion
Study: 27155968
Drug: Animal-assisted activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-assisted activity (AAA) with a dog, 30 min sessions, twice a week for 12 weeks
Study: 14517494
Drug: Melagatran 0.1-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melagatran 0.1-5 mg single subcutaneous doses
Study: 14517494
Drug: Melagatran 3
Normalized name: melagatran
DrugBank: Melagatran (DB13616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melagatran 3 mg subcutaneous doses every 12 hours for 4 days
Study: 343913
Drug: 2alpha, 3alpha-epithio-5alpha-androstan-17beta-yl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2alpha, 3alpha-epithio-5alpha-androstan-17beta-yl 1-methoxycyclopentyl ether (mepitiostane) 10 mg b.i.d.
Study: 343913
Drug: Fluoxymesterone 10
Normalized name: fluoxymesterone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxymesterone 10 mg b.i.d. (Control)
Study: 27259311
Drug: Phenylephrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (50 μg/min)
Study: 27259311
Drug: Ephedrine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (4 mg/min)
Study: 24362908
Drug: Cryotherapy using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy using frozen gel gloves
Study: 22650317
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera gel (5 mg applied topically three times daily for 3 months)
Study: 22650317
Drug: Antioxidant capsules
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant capsules (twice daily for 3 months)
Study: 19250006
Drug: Ginger 250
Normalized name: ginger root 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger 250 mg capsules for 4 days
Study: 15726523
Drug: Daily subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous injection of amifostine
Study: 15726523
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus infusions of amifostine
Study: 15726523
Drug: Standard (once-daily)
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard (once-daily) radiation therapy alone
Study: 15726523
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy with standard radiation therapy
Study: 15726523
Drug: Hyperfractionated (twice-daily)
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated (twice-daily) radiation therapy plus concomitant chemotherapy
Study: 7661347
Drug: 40‐cm2 fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40‐cm2 fentanyl patch and a 60‐cm2 placebo patch
Study: 7661347
Drug: 60‐cm2 fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60‐cm2 fentanyl patch and a 40‐cm2 placebo patch
Study: 3295129
Drug: Adr (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adr (60 mg/m2 IV on day 1) and DTIC (250 mg/m2 every 3 weeks)
Study: 3295129
Drug: Adr (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adr (60 mg/m2 IV on day 1), DTIC (250 mg/m2 every 3 weeks), and Cyclophosphamide (500 mg/m2 on day 1)
Study: 3295129
Drug: Adr (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adr (60 mg/m2 IV on day 1), DTIC (250 mg/m2 every 3 weeks), and Actinomycin D (1.2 mg/m2 on day 1)
Study: 25641922
Drug: CLA80:20 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLA80:20 (4 g/day)
Study: 24119523
Drug: Intralesional betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional betamethasone (1.4 mg)